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Abstract 
Background:  Neurofibromatosis 1 (NF1) is an autosomal dominantly inherited disorder 
caused by a spectrum of mutations affecting the Nf1 gene. Affected patients develop benign 
and malignant tumors at an increased frequency. Clinical findings include multiple café-au-lait 
cutaneous pigmentations, neurofibromas, axillary freckling, optic gliomas, benign iris 
hamartomas (Lisch nodules), scoliosis, and poorly defined soft tissue lesions of the skeleton. 
Kerl first reported an association of NF1 with multiple central giant cell granulomas (CGCGs) 
of the jaws. There have since been 4 additional published cases of NF1 patients with CGCGs 
of the jaws.  
Clinical Cases: We report on 2 patients who presented with NF1 and aggressive CGCGs of 
the jaws. In both cases, the clinical course was characterized by numerous recurrences 
despite mechanical curettage and surgical resection.  
Conclusions:  We review proposed mechanisms to explain the apparent association 
between NF1 and an increased incidence of CGCGs of the jaws. While the presence of 
CGCGs of the jaws in patients with NF1 could represent a coincidental association or a true 
genetic linkage, we propose that this phenomenon is most likely related to NF1-mediated 
osseous dysplasia. Compared to normal bone, the Nf1-haploinsufficient bone in a patient with 
NF1 may be less able to remodel in response to as of yet unidentified stimuli (e.g. excessive 
mechanical stress and/or vascular fragility), and consequently may be more susceptible to 
developing CGCG-like lesions. Alternatively, the CGCG in NF1 patients could represent a 
true neoplasm, resulting from additional, as of yet unidentified, genetic alterations to Nf1-
haploinsufficient bone.
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Introduction  
  Neurofibromatosis 1 (NF1) is a relatively common (1:3,500 newborns1) autosomal 
dominantly inherited genetic disorder, caused by a spectrum of mutations affecting the 
neurofibromatosis 1 (Nf1) gene. The Nf1 gene is located at 17q11.2, spans more than 350 
Kbs and comprises 60 exons. To date, more than 200 separate mutations have been 
identified.2 About 50% of NF1 cases occur in patients with unaffected parents and are 
believed to represent spontaneous mutations.  
  Mutations3 range from nonsense point mutations that introduce stop codons (30-
40%), missense mutations that alter the amino acid sequence (5-10%), microdeletions (5-
10%), to intron mutations that affect splicing (20-35%). Approximately 2-10% of cases are 
believed to be due to large (1.5Mb) gene deletions that also involve portions of neighboring 
non-Nf1 related coding sequences. With few exceptions, attempts to correlate phenotypical 
expression to genotype have been largely unsuccessful.  
  The heterogeneous nature of Nf1 mutations and the relatively high rate of new 
mutations makes molecular testing difficult.  Linkage analysis, with the goal of identifying 
chromosomes that carry the Nf1 mutation, is generally effective for prenatal diagnosis. Direct 
mutational analysis is rarely performed outside of the research laboratory. In most cases, 
however, a diagnosis of NF1 can be reached based on clinical diagnostic criteria originally 
established by the 1987 National Institutes of Health Neurofibromatosis Consensus 
Development Conference (Table 1). 
  In addition to the diagnostic criteria listed in Table 1, affected patients are prone to 
developing a number of specific neoplastic and non-neoplastic conditions at an increased 
frequency.  The most commonly encountered tumors in patients with NF1 include 
neurofibromas and optic gliomas. Malignant peripheral nerve sheath tumors develop from 
pre-existing plexiform neurofibromas in approximately 2-16% of patients4, and are the leading 
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cause of death in NF1 patients.  Pheochromocytomas and juvenile chronic myeloid leukemia 
are also seen with increased frequency. Examples of common non-neoplastic conditions 
include poorly-characterized high signal intensity lesions on T2-weighted Magnetic 
Resonance (MR) images of the brain known as “unidentified bright objects”, learning 
disabilities, seizures, secondary hypertension and macrocephaly. Commonly seen soft tissue 
lesions in the oral cavity include neurofibromas and enlarged fungiform papillae.5  
  Skeletal findings include scoliosis-like spinal curvature, short stature, tibial 
pseudoarthrosis and dysplastic lesions of the skeleton. Certain osseous abnormalities, such 
as sphenoid dysplasia, are considered a diagnostic feature for NF1 (Table 1). Although not 
restricted to NF1, over 50% of patients with an osseous defect of the greater wing of the 
sphenoid bone have NF1. The nature of these hard tissue lesions is poorly defined, but can 
involve bones that develop by both intramembranous and endochondral ossification. These 
lesions are generally assumed to represent abnormal development of mesodermal elements 
and hence are considered primary osseous dysplasias. In some, but not all cases, an adjacent 
neurofibroma or other soft tissue lesion that is presumed to directly erode bone is implicated.  
  Skeletal lesions specific to the jaws include6 enlarged mandibular foramen and 
canals, branched mandibular canals, widening of the coronoid notch, deformity of the 
condylar head, lengthening of the condylar neck, irregularity of the inferior mandibular cortex, 
intrabony cyst-like lesions and thinning and lateral bowing of the ramus. Also noted on CT 
analysis is the presence of an increased amount of fat-like soft tissue immediately adjacent to 
the affected ramus. 
  We report 2 patients with NF1 who presented with aggressive central giant cell 
granulomas (CGCGs) of the jaws. In both cases, the clinical course was characterized by 
significant osseous destruction, poor response to treatment and numerous recurrences. 
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Case Presentation: 
Case 1:  
 In 1996, a12 year-old boy presented with a large mass of the right palate. Intra-oral 
examination revealed significant palatal expansion (Figure 1). The lesion crossed the midline, 
and extended to both the soft palate and the buccal vestibule. The extent of maxillary 
destruction was evident on coronal (Figure 2a) and axial (Figure 2b) Computed Tomography 
(CT) scans.  
 The patient’s past medical history was significant for Neurofibromatosis 1, diagnosed 
when the patient was 3 years old. Besides multiple café-au-lait macules, axillary freckling and 
bilateral Lisch nodules, the patient also had multiple neurofibromas, a number of which 
involved the spine. He was the only child of unaffected parents. The patient was taking 
fluoxetine hydrochloride and gabapentin secondary to chronic spinal pain. 
Incisional biopsy of the lesion revealed aggregates of multinucleated giant cells in a 
background of cellular fibrous connective tissue with foci of hemorrhage, consistent with 
CGCG (Figure 3). Serum parathyroid hormone (PTH) and calcium were within normal limits. 
The patient was taken to the operating room and a right hemi-maxillectomy was performed. 
The surgical line of resection was extended to the left maxillary central incisor site. Histologic 
examination of the resected specimen was consistent with that of a CGCG.  
 The patient was lost to follow up until December 2002, at which time he presented 
with a recurrent palatal mass involving the remaining portion of the right maxilla, the left 
anterior alveolar process and anterior hard palate (Figure 4). CT imaging (Figure 5) 
demonstrated that the lesion extended to the left premolar region, the right infra-orbital rim, 
the right nasal septum and the pterygoid plate. Again, biopsy of the lesion was consistent with 
a recurrent central giant cell granuloma. The recurrent lesion was surgically excised via a left 
anterior completion hemi-maxillectomy. The surgical site extended laterally to the left 
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maxillary canine region. In April of 2003, the maxillary defect (Figure 6) was reconstructed 
with a vascularized free fibular graft. During graft harvesting, a markedly enlarged peroneal 
nerve was noted (Figure 7). At one year follow-up, no evidence of recurrence was noted. 
 
Case 2:  
  A 34 year old female presented with fullness of her right mandibular symphysis area. 
Her past medical history was significant for a CGCG of the anterior mandible that had been 
resected at10 years of age. Serum parathyroid hormone (PTH) and calcium were within 
normal limits. At age 20, the patient underwent reconstructive surgery with autologous bone 
grafting and osseointegrated dental implants. During the procedure, a small osseous defect 
was noted in the surgical field, which on histological examination proved to be a recurrent 
CGCG. The lesion was treated by peripheral ostectomy. Five years later, the patient’s son 
was diagnosed with NF1. Subsequent to this, the patient and her parents were sent to a 
Medical Geneticist for assessment. It was determined, based on clinical presentation, that 
both the patient and her father had NF1.   
  Radiographic examination (Figure 8) revealed numerous radiolucent lesions 
surrounding the mandibular implants, bilateral maxillary and right mandibular lesions. 
Intralesional injection of triamcinolone (according to the protocol established by Carlos and 
Sedano7) over an eight month period failed to result in any radiographically-evident 
improvement. The lesions were surgically debrided, and the patient was placed on an 
investigational bisphosphonate protocol. 
 
Discussion 
  Central giant cell granuloma (CGCG) is a benign central lesion of bone, primarily 
involving the jaws, of variably aggressive nature characterized by8 aggregates of 
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multinucleated giant cells in a background of cellular vascular fibrous connective tissue and 
spindle-shaped mononuclear stromal cells, often with extravasation of red blood cells. 
Currently there are no reliable criteria for correlating clinical aggressiveness with histological 
presentation9. Recurrences are not uncommon, with an estimated 5 year disease-free 
success rate of only 75% following conventional surgical therapy.10 The rate of recurrence is 
even more prominent among young males. 
  CGCG most likely represents a non-neoplastic reactive process.11 Proposed etiologies 
include intraosseous hemorrhage12, trauma13, faulty bone development and abnormal repair 
of bone. Arguing in favor of a reactive process is the occasional association of CGCGs with 
other pre-existing bone lesions, such as fibrous dysplasia,14 Pagets disease of bone15, central 
odontogenic fibroma16,17, traumatic bone cyst18 and ossifying fibroma19,20. However, the 
possibilities that some subtypes of CGCG of the jaws (e.g. those associated with syndromes) 
may represent a neoplastic process21,22, akin to the giant cell tumor of bone,23,24 or have a 
systemic component,25 has not been conclusively ruled out. 
  In CGCGs, the multinucleated giant cells (MGCs) are often concentrated in areas of 
hemorrhage, adjacent to blood vessels. Although the MGCs seen in CGCG share some 
similarities with the osteoclast26,27, there are enough phenotypic differences to suggest that 
these may not be true osteoclasts28. It is generally accepted that these MGCs develop as a 
result of cell-cell fusion of mononuclear cells29.  Possible origins of these mononuclear cells 
include endothelial cells30, myofibroblasts31, macrophages, or mononuclear hematopoietic 
progenitor cells of myeloid lineage.26  
 A number of conditions can present with lesions that histologically are 
indistinguishable from the central giant cell granuloma (CGCG) of bone, including brown 
tumors of hyperparathyroidism, cherubism, and, less commonly, a number of inherited 
syndromes. These include Ramon syndrome (gingival fibromatosis, hypertrichosis, epilepsy, 
mental and somatic retardation and cherubism-like lesions)32, Schimmelpenning syndrome33, 
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Noonan syndrome34,35 (short stature, ocular hypertelorism, pulmonic stenosis, webbed neck), 
“Noonan-like syndrome, cherubism, and polyarticular pigmented villonodular synovitis” 
(additional findings of multiple lesions of pigmented villonodular synovitis affecting multiple 
weight-bearing bones) and "ocular-ectodermal syndrome"36.   
 Interestingly, NF1 demonstrates phenotypic overlap with Noonan syndrome in 
approximately 12% of patients and multiple giant cell lesions have been reported in patients 
with Noonan syndrome.34,35 Missense mutations in the gene PTPN1137, which encodes the 
non-receptor tyrosine phosphatase protein SHP-2 38 and is responsible for Noonan 
syndrome, were identified in two siblings inheriting Noonan-like/ multiple giant cell lesions 
syndrome39 and in one patient who progressed from Noonan syndrome to multiple 
lentigines/LEOPARD syndrome and ultimately to Noonan-like/ multiple giant cell lesions 
syndrome.40 Moreover, there has been one report of a patient with NF1-Noonan-like 
phenotype with a solitary CGCG of the jaws.41 This NF1-Noonan-like phenotype is believed 
to represent 2 separate conditions.  Watson syndrome, characterized by overlapping mild 
features of both NF1 and Noonan-like syndrome has been linked to the Nf1 gene. NF1-
Noonan syndrome, an entity of its own right, is believed to be the result of the independent 
segregation of a both classical NF1 phenotype and a Noonan syndrome phenotype. 42The 
observation that the genes responsible for these 2 conditions are located on separate 
chromosomes does not rule out the possibility of an as yet undefined interaction between 
neurofibromin and the Noonan syndrome gene product SHP-2. However, the basis for this 
apparent association between these 2 conditions and CGCGs of the jaws remains unclear. 
 Kerl43 first reported an association of NF1 with multiple CGCGs of the jaws. Excluding 
the  patient with neurofibromatosis-Noonan syndrome41, there have been 4 additional reports of 
multiple CGCGs in patients with NF1.44,45,46,47 Molecular analysis of one of these cases47 
uncovered a novel Nf1 splice mutation in the proband, resulting in the deletion of 53 amino acids 
within the GTPase-activating domain of neurofibromin. Additional cases of a giant cell tumor of 
  8 
the occipital bone48 and a patient with multiple “peripheral” giant cell granulomas49 associated 
with extensive resorption of the underlying bone have also been reported. 
  The apparent association between NF1 and an increased incidence of CGCGs of the 
jaws could represent a coincidental association, a genetic linkage or an underlying 
susceptibility to developing CGCG-like lesions in qualitatively abnormal bone.  
  Arguing against a coincidental association is the relative rarity of CGCG. A Dutch 
study50 reviewing all histologically confirmed cases of CGCG of the jaws in Holland over a 
five year period reported an incidence of 0.00011%. Of 83 cases of CGCG identified, 2 
patients had NF1 and 1 patient had NF1 with a Noonan-like phenotype. This represents at 
least 3.6% of all cases of CGCGs, a 100-fold increase over the estimated prevalence of NF1 
(0.029% of the population2). Moreover, multiple CGCGs are very rare in the absence of 
hyperparathyroidism or cherubism. 
  Alternatively, the association between NF1 and CGCG could represent a true genetic 
linkage; resulting from defects or deletions of two or more genes that map near each other on 
the same region of a chromosome. Arguing against a genetic linkage is the lack of direct 
evidence of a specific genetic basis for CGCG. 
  We believe that the increased incidence of CGCGs of the jaws in patients with NF1 
most likely represents an inherent susceptibility to intraosseous trauma and/or hemorrhage in 
bone previously altered by an underlying osseous dysplasia. This qualitatively abnormal bone 
would be more susceptible to developing CGCG-like lesions in response to as of yet 
unidentified factors such as excessive mechanical stress and/or vascular fragility.  
In addition to sphenoid dysplasia, patients with NF1 have an increased incidence of 
additional skeletal dysplasias including scoliosis, thinning and/or bowing of the weight bearing 
long bones, pseudoarthrosis, and ill-defined fibrocystic lesions of bone51.    
 Although little is known about the underlying basis for the development of dysplastic bone 
in NF152, several possible mechanisms have been proposed. These include a direct pressure 
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effect from adjacent excessive soft tissue on developing and/or remodeling bone, altered 
function of the Nf1 gene product (neurofibromin), or loss of function of other genes coded for 
either within or contiguous to the deleted portion of the Nf1 gene.  
  Traditionally, the presence of altered bone in NF1 has been attributed to a direct 
pressure effect of excessive soft tissue, presumably from an adjacent neurofibroma, on 
developing and/or remodeling bone. However, this fails to account for the significant number 
of cases in which adjacent neurofibromas cannot be demonstrated. For example, histological 
analysis of a large number of biopsies from patients with tibial pseudoarthrosis53, which is 
seen in 1-4% in children with NF1, revealed the presence of neurofibroma-like tissue in only 
40% of cases. In 45% of cases, a highly cellular non-specific fibrovascular tissue devoid of 
neural/Schwannian elements is noted. 
  The role of the Nf1 gene in skeletal development has not been well characterized, 
although the demonstration of Nf1 mRNA expression and its protein product, neurofibromin, 
in both osteoblasts and osteoclasts suggests that it may play a role in both osteogenesis and 
bone homeostasis54. Specifically, the Nf1 gene codes for the neurofibromin protein, a putative 
tumor suppressor protein with GTPase-activating function that appears to be involved in the 
down regulation of ras signal transduction55. Ras activation plays an important role in cellular 
proliferation and differentiation. Nf1 mutations would therefore be expected to result in 
increased ras signal transduction. In support of this, it has been demonstrated54 that mice 
embryos heterozygous for Nf1 have higher levels of a number of specific downstream 
products of ras activation (phosphorylated p42 and p44 MAP kinases).  
  Yu et al56 recently demonstrated that Nf1+/- (haploinsufficient) mice had normal bone 
mass but a tendency to decreased bone homeostasis compared to wild type. Specifically, 
loss of one Nf1 allele was associated with deregulated Ras signaling in bone marrow 
osteoprogenitor cells, decreased osteoblastic induction potential and premature apoptosis of 
osteoblasts. However, Nf1 haploinsuffiency alone was not sufficient to cause bone lesions, 
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suggesting that other events (e.g. loss of the remaining Nf1 allele, loss of an additional gene 
or an adverse change in the microenvironment) are required prior to the development of 
pathologic changes in the bone. 
  Abdel-Wanis and Kawahara57 have proposed several mechanisms by which 
decreased neurofibromin function could result in altered bone formation. Under normal 
conditions, ras activation negatively regulates type I collagen synthesis58, the major organic 
constituent of bone. In Nf1 mutations, increased ras activity would be expected to result in a 
decrease in type I collagen gene expression. The resultant collagen-deficient bone would 
have a decreased ability to respond to functional demands, and hence would be more prone 
to developing intraosseous defects. In addition, a predisposition to developing increased 
amounts of architecturally abnormal granulation tissue has been demonstrated in 
experimentally-induced skin wounds in mice heterozygous for the Nf1 gene (Nf1+/-).59 
Theoretically, a similar osteoblastic response to trauma could lead to an abnormal reparative 
process within bone characterized by the deposition of atypical fibrous connective tissue. A 
third explanation may be related to the identification of three genes, normally transcribed from 
the opposite strand of Nf1, within one of the Nf1 introns. These are: OMgp (oligodendrocyte-
myelin glycoprotein), EVI2B (ecotropic viral insertion site 2 protein B) and EVI2A (ecotropic 
viral insertion site 2 protein A). While the exact role of these 3 proteins is poorly 
characterized, OMgp appears to block activation of the c-fos proto-oncogene via alteration of 
platelet-derived growth factor function60. Increased levels of c-fos mRNA have been identified 
in the bone lesions of patients with fibrous dysplasia61. Therefore, it is possible that in cases 
of NF1 in which the deletion includes the gene for OMgp, the resultant increased levels of c-
fos could predispose to the development of a fibrous dysplasia-like bone.  
  The observation that Nf1 haploinsuffiency alone is not sufficient to cause bone 
lesions56 implies that other events (e.g. loss of the remaining Nf1 allele, loss of an additional 
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gene or an adverse change in the microenvironment) are required prior to the development of 
CGCG-like lesions in the bone.  
 
Conclusion 
  We report 2 patients with NF1 who presented with central giant cell granulomas 
(CGCGs) of the jaws. In both cases, the clinical course was characterized by significant 
osseous destruction and recurrence. 
  While the presence of CGCGs of the jaws in patients with NF1 could represent a 
coincidental association or a genetic linkage, we propose that this phenomenon is most likely 
related to NF1-mediated osseous dysplasia. Compared to normal bone, the Nf1-
haploinsufficient bone in a patient with neurofibromatosis 1 may be less able to remodel in 
response to as of yet unidentified stimuli (e.g. excessive mechanical stress and/or vascular 
fragility), and consequently may be more susceptible to developing CGCG-like lesions. 
Alternatively, the CGCG in NF1 patients could represent a true neoplasm, resulting from 
additional, as of yet unidentified, genetic alterations to Nf1-haploinsufficient bone. 
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Figure 1: Case 1. Clinical photograph of 12 year old male at initial presentation. There is a 
large expansile mass of the right palate, which crosses the midline. 
 
Figure 2a: Case 1. Coronal CT scan of patient at initial presentation demonstrates large 
lesion expanding the right maxilla. The lesion occupies the entire maxillary antrum and 
extends into the nasal fossa. 
 
Figure 2b: Case 1. Axial CT scan of patient at initial presentation demonstrates large lesion 
expanding the right maxilla. The outer cortical plate of bone is focally destroyed. 
 
Figure 3: Case 1. Histologic examination of tissue removed at incisional biopsy revealed 
aggregates of multinucleated giant cells in a cellular fibrous connective tissue background. 
Also noted are foci of hemorrhage. Hematoxylin and eosin stain. Initial magnification 40x. 
 
Figure 4: Case 1. Clinical photograph of patient at follow-up (age 18).  There is a recurrent 
palatal mass involving both the remaining portion of the right maxilla, the left anterior maxilla 
and the anterior hard palate. 
 
Figure 5: Case 1: Coronal CT scan of patient at follow up. A recurrent multilocular lesion is 
evident involving the right maxillary antrum and nasal fossa. 
 
Figure 6: Case 1: The extent of bone destruction is evident on this post-operative 3-
Dimensional CT reconstruction. 
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Figure 7: Case 1. During graft harvesting to reconstruct maxilla with a vascularized free 
fibular graft, a markedly enlarged peroneal nerve was noted. 
 
Figure 8: Case 2: Panoramic radiograph of 34 year old female who presented with fullness 
of her right mandibular symphysis area. Numerous radiolucent lesions involving the anterior 
and right posterior mandible and the bilateral maxilla are noted. 
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Table 1: Diagnostic Criteria for Neurofibromatosis 1  
(1987 National Institutes of Health Consensus Development Conference62)  
 
The diagnostic criteria for NF-1 are met in an individual if two or more of the following 
are found:  
• Six or more café-au-lait macules over 5 mm in greatest diameter in prepubertal 
individuals and over 15 mm in greatest diameter in postpubertal individuals.  
• Two or more neurofibromas of any type or one plexiform neurofibroma.  
• Freckling in the axillary or inguinal region.  
• Optic glioma.  
• Two or more Lisch nodules (iris hamartomas).  
• A distinctive osseous lesion such as sphenoid dysplasia or thinning of long bone cortex 
with or without pseudarthrosis.  
• A first-degree relative (parent, sibling, or offspring) with NF-1 by the above criteria. 
 
    Note: Although not part of the NIH Consensus Development Conference 
recommendations, it has been recommended that infants with multiple café-au-lait macules 
should be reassessed annually until age 10 years for the development of additional 
diagnostic criteria63. 
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Table 1: Diagnostic Criteria for Neurofibromatosis 1  
(1987 National Institutes of Health Consensus Development Conferencei)  
 
The diagnostic criteria for NF-1 are met in an individual if two or more of the following 
are found:  
• Six or more café-au-lait macules over 5 mm in greatest diameter in prepubertal 
individuals and over 15 mm in greatest diameter in postpubertal individuals.  
• Two or more neurofibromas of any type or one plexiform neurofibroma.  
• Freckling in the axillary or inguinal region.  
• Optic glioma.  
• Two or more Lisch nodules (iris hamartomas).  
• A distinctive osseous lesion such as sphenoid dysplasia or thinning of long bone cortex 
with or without pseudarthrosis.  
• A first-degree relative (parent, sibling, or offspring) with NF-1 by the above criteria. 
 
    Note: Although not part of the NIH Consensus Development Conference 
recommendations, it has been recommended that infants with multiple café-au-lait macules 
should be reassessed annually until age 10 years for the development of additional 
diagnostic criteriaii. 
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i Neurofibromatosis. NIH Consens Statement 1987 Jul 13-=15; 6:1-19. 
ii Gutman DH, Aylsworth A, Carey J, Korf B, Marks J, Pyeritz RE, et al. The diagnostic 
evaluation and multidisciplinary management of neurofibromatosis 1 and 
neurofibromatosis 2. JAMA 1997;278:51-7. 
